Abstract
Schmidt et al (1) showed that MR imaging by using gadofluorine M, a fluorinated macrocyclic gadolinium-based contrast agent, enabled detection of disease progression in a model of muscular dystrophy in mice, whereas a macromolecular contrast agent did not. MR imaging with contrast agents such as gadofluorine M might ultimately be used in patients with muscular dystrophy to monitor disease progression and to assess the effectiveness of newer therapies currently under development.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
